R
Ranjan Pathak
Researcher at Yale University
Publications - 109
Citations - 1382
Ranjan Pathak is an academic researcher from Yale University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 17, co-authored 99 publications receiving 1047 citations. Previous affiliations of Ranjan Pathak include University of Tennessee Health Science Center.
Papers
More filters
Journal ArticleDOI
YouTube as a Source of Information on Ebola Virus Disease.
Ranjan Pathak,Dilli Ram Poudel,Paras Karmacharya,Amrit Pathak,Madan Raj Aryal,Maryam Mahmood,Anthony A. Donato +6 more
TL;DR: Although YouTube seems to generally be a useful source of information on the current outbreak, increased efforts to disseminate scientifically correct information is desired to prevent unnecessary panic among the among the general population.
Journal ArticleDOI
Rituximab-induced serum sickness: A systematic review
Paras Karmacharya,Dilli Ram Poudel,Ranjan Pathak,Anthony A. Donato,Sushil Ghimire,Smith Giri,Madan Raj Aryal,Clifton O. Bingham +7 more
TL;DR: It is important to recognize RISS clinically, as it may mimic exacerbation of various rheumatologic conditions, and further infusions of rituximab should be avoided, asIt may provoke more severe symptoms.
Journal ArticleDOI
Left atrial appendage aneurysm: a systematic review of 82 cases.
Madan Raj Aryal,Fayaz A. Hakim,Sailu Ghimire,Sushil Ghimire,Smith Giri,Anil Pandit,Yashoda Bhandari,Naresh Bhandari,Ranjan Pathak,Paras Karmacharya,Rajesh Pradhan +10 more
TL;DR: This systematic review sought to systematically review the published literature on left atrial appendage aneurysm to address its demographic features, clinical characteristics, treatment, complications, and outcomes.
Journal ArticleDOI
Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study
Smith Giri,Ranjan Pathak,Madan Raj Aryal,Paras Karmacharya,Vijaya Raj Bhatt,Michael Gary Martin +5 more
TL;DR: To the editor: in recent years, there has been growing evidence that hospital volume affects survival among patients undergoing a variety of surgical procedures and medical treatments.
Journal ArticleDOI
Eculizumab in Transplant-Associated Thrombotic Microangiopathy
TL;DR: It is demonstrated that eculizumab use may result in high response rate and 1-year survival in patients with TA-TMA refractory to discontinuation of calcineurin inhibitor and plasma exchange.